Intravitreal sustained-release dexamethasone implant for the treatment of postoperative cystoid macular edema following vitrectomy
- 26 March 2026
- journal article
- research article
- Published by Springer Nature in International Ophthalmology
- Vol. 46 (1) , 178
Abstract
Aim Previous findings have demonstrated that intravitreal sustained-release dexamethasone (DEX) implants improve functional and anatomical outcomes in patients with cystoid macular edema (CME) following cataract surgery; however, data on the influence of different surgical indications remain limited. This study aims to evaluate the efficacy of DEX implants in patients with persistent postoperative CME following vitrectomy, and to assess differences in treatment response regarding surgical indication, phakic status, and prior treatment received before DEX. Methods In this single-center study, we retrospectively reviewed data from 57 patients (57 eyes) who received a DEX implant for persistent postoperative CME following vitrectomy; main outcome measures were change in best corrected visual acuity (BCVA) and central retinal thickness (CRT). We then measured the effect of treatment outcomes across subgroups of patients according to surgical indication (rhegmatogenous retinal detachment vs. epiretinal membrane), phakic status, and prior receipt of subtenon triamcinolone. Results Patient eyes receiving a DEX implant achieved a significant improvement in both functional and anatomical outcomes: BCVA gain, 0.53 to 0.47 logMAR (p = 0.0180); CRT reduction, 453.5 µm to 381.6 µm (p < 0.0001). The mean number of DEX implants received was 1.74, with no significant differences observed between patient subgroups. Subgroup comparisons did not show any significant impacts on BCVA or CRT by either surgical indication or type of surgery. Conclusion Sustained-release DEX implants provided immediate and lasting functional and anatomical benefits in patients with persistent postoperative CME. Outcomes such as the required number of DEX implants or treatment response were not significantly impacted by subgroup factors.Keywords
This publication has 25 references indexed in Scilit:
- Cystoid macular edema after vitrectomy and after phacovitrectomy for epiretinal membraneCanadian Journal of Ophthalmology, 2023
- Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and managementSurvey of Ophthalmology, 2020
- Long-Term Intravitreal Dexamethasone Implant Outcomes in UveitisOcular Immunology and Inflammation, 2019
- Risk Factors and Incidence of Macular Edema after Cataract SurgeryOphthalmology, 2016
- Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndromeJournal of Cataract & Refractive Surgery, 2015
- Cystoid macular edema after pars plana vitrectomy for idiopathic epiretinal membraneGraefe's Archive for Clinical and Experimental Ophthalmology, 2014
- Incidence of Postvitrectomy Macular Edema Using Optical Coherence TomographyOphthalmology, 2009
- Dexamethasone Posterior-Segment Drug Delivery System in the Treatment of Macular Edema Resulting from Uveitis or Irvine-Gass SyndromeAmerican Journal of Ophthalmology, 2009
- Prostaglandins and Cystoid Macular EdemaSurvey of Ophthalmology, 2002
- The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiologyActa Ophthalmologica Scandinavica, 2001